Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. Lesiak

The research site in Lodz, Poland, is advancing care for immune system diseases by testing new JAK‑inhibitor treatments in children and adolescents.

• Evaluation of ruxolitinib cream for moderate atopic dermatitis
• Focus on patients with inadequate response to standard topicals
• Emphasis on safety and efficacy in the pediatric population

These studies aim to provide alternative options when conventional therapies are insufficient, improving quality of life for young patients with inflammatory skin conditions.

At Dermoklinika Centrum Medyczne, investigators are exploring innovative oral agents for severe hair‑loss disorders, a key area within skin and connective tissue diseases.

• Assessment of ritlecitinib versus placebo for scalp hair regrowth in pediatric alopecia areata
• Targeting the underlying immune pathways that drive hair follicle loss
• Monitoring long‑term outcomes and tolerability in children

The goal is to establish an effective, disease‑modifying therapy that can restore hair and confidence for children affected by this autoimmune condition.